FDA Endorses Expedited Approval Pathway for Wave's RNA-Editing Therapy in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences has received FDA alignment on a registrational pathway for WVE-006, an investigational RNA-editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The planned two-year trial includes an interim analysis after one year for potential accelerated approval based on biomarkers, eliminating the need for a separate confirmatory study. The therapy, administered via infrequent subcutaneous dosing, aims to address both lung and liver complications of AATD while avoiding the off-target edits associated with DNA base editing approaches.

Wave Life Sciences has secured FDA agreement on an efficient development strategy for WVE-006, an RNA-based therapeutic designed to treat alpha-1 antitrypsin deficiency by correcting the genetic mutation responsible for the condition. The proposed trial structure—a single two-year study with an interim checkpoint at twelve months—streamlines the regulatory process by potentially enabling accelerated approval without requiring a subsequent validation trial. This approach represents a shift in how the agency evaluates treatments for rare genetic disorders affecting protein production.

The therapy targets a specific population of approximately 200,000 homozygous carriers in North America and Europe. Current treatment relies on intravenous protein replacement, which has limitations including inconsistent protective levels during disease episodes and inability to prevent liver complications. WVE-006 seeks to address both pulmonary and hepatic manifestations through subcutaneous administration at infrequent intervals, while avoiding genomic damage risks associated with alternative editing technologies.